Thus, the establishment of non-human primate models of PINK1-Parkin-associated PD that reproduce PD-like phenotypes and the evaluation of drug properties including pharmacokinetic profiles and potential adverse effects using these mammalian models are required in the future studies. This evidence concerns the gene PRKN and Parkinson disease.